T-Knife GmbH news

• Preclinical, Translational and Clinical Trial Posters for TK-8001 Presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
• Plan to initiate a first-in-human, Phase 1/2 Trial in Early 2022

T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, reported preclinical data demonstrating that its novel MAGE-A1-specific T cell receptor (TCR) induced meaningfu

T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that three abstracts highlighting its lead product candidate TK-8001, a T cell receptor (TCR) engineered T cell therapy (TCR-T) being developed to treat MAGE-A1 positive solid tumors, will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting taking place November 10-14, 2021.

“TK-8001 is a novel CD8 TCR-T targe

T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with participation from other new investors including, LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Manage

T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties
- Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF